Patents by Inventor Samantha J. Busfield

Samantha J. Busfield has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230416356
    Abstract: The present disclosure relates to an antigen-binding molecule that specifically binds to interleukin-31 (IL-31), wherein the antigen-binding molecule comprises an immunoglobulin heavy chain variable domain and an immunoglobulin light chain variable domain.
    Type: Application
    Filed: November 22, 2021
    Publication date: December 28, 2023
    Inventors: Samantha J. BUSFIELD, Matthew J. WILSON
  • Publication number: 20230391862
    Abstract: Provided are methods for suppressing an immune response to a therapeutic protein encoded by a vector in a subject in need thereof and associated compositions. The method may include selecting a subject as the subject in need of treatment with the vector and then administering to the subject a composition comprising the therapeutic protein or a homolog or functional variant thereof, optionally an immunologically related variant thereof.
    Type: Application
    Filed: October 20, 2021
    Publication date: December 7, 2023
    Inventors: Samantha J. BUSFIELD, Matthew J. WILSON
  • Publication number: 20230365670
    Abstract: The present disclosure relates to an antigen-binding molecule that specifically binds to nerve growth factor (NGF) and uses thereof.
    Type: Application
    Filed: June 21, 2023
    Publication date: November 16, 2023
    Inventors: Samantha J. BUSFIELD, Matthew J. WILSON
  • Patent number: 8137923
    Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: January 20, 2010
    Date of Patent: March 20, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Samantha J. Busfield, Jean-Luc Villeval
  • Publication number: 20110020798
    Abstract: Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST proteins, the invention further provides isolated ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST fusion proteins, antigenic peptides and anti-ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST antibodies. The invention also provides ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: December 18, 2009
    Publication date: January 27, 2011
    Inventors: Douglas A. Holtzman, Sean A. McCarthy, Kyle J. MacBeth, Samantha J. Busfield, Yang Pan, David White, Mehran M. Khodadoust, Wei Gu
  • Publication number: 20100279313
    Abstract: The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.
    Type: Application
    Filed: June 30, 2008
    Publication date: November 4, 2010
    Inventor: Samantha J. Busfield
  • Publication number: 20100261200
    Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: January 20, 2010
    Publication date: October 14, 2010
    Inventors: Samantha J. Busfield, Jean-Luc Villeval, Martine Jandrot-Perrus, William Vainchencker
  • Patent number: 7803564
    Abstract: The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1,2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-?. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: September 28, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Samantha J. Busfield, David P. Gearing
  • Publication number: 20090286956
    Abstract: The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted.
    Type: Application
    Filed: October 12, 2007
    Publication date: November 19, 2009
    Inventors: Sean A. McCarthy, David P. Gearing, Douglas A. Holtzman, Yang Pan, Samantha J. Busfield, Thomas M. Barnes, Charles R. Mackay, Jose M. Lora
  • Publication number: 20090117583
    Abstract: The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1,2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-?. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Application
    Filed: September 26, 2007
    Publication date: May 7, 2009
    Inventors: Samantha J. Busfield, David P. Gearing
  • Publication number: 20080248477
    Abstract: Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST proteins, the invention further provides isolated ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST fusion proteins, antigenic peptides and anti-ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST antibodies. The invention also provides ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: December 11, 2007
    Publication date: October 9, 2008
    Inventors: Douglas A. Holtzman, Sean A. McCarthy, Kyle J. MacBeth, Samantha J. Busfield, Yang Pan, David White, Mehran M. Khodadoust, Wei Gu
  • Publication number: 20080220495
    Abstract: The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted.
    Type: Application
    Filed: October 12, 2007
    Publication date: September 11, 2008
    Inventors: Sean A. McCarthy, David P. Gearing, Douglas A. Holtzman, Yang Pan, Samantha J. Busfield, Thomas M. Barnes, Charles R. Mackay, Jose M. Lora
  • Patent number: 7408038
    Abstract: The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: August 5, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Samantha J. Busfield
  • Patent number: 7294482
    Abstract: The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1, 2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-?. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The ELVIS nucleic acids of the present invention are useful as modulating agents in regulating a variety of cellular processes, and are particularly useful for diagnostic, screening and therapeutic methods for the treatment of skin conditions, such as for wound healing.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: November 13, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Samantha J. Busfield, David P. Gearing
  • Patent number: 7291714
    Abstract: The invention provides isolated nucleic acid molecules and polypeptide molecules that encode glycoprotein VI, a platelet membrane glycoprotein that is involved platelet-collagen interactions. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: November 6, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Samantha J. Busfield, Jean-Luc Villeval
  • Patent number: 7202029
    Abstract: The invention concerns cDNA molecules encoding TANGO 191 and TANGO 195, both of which are transmembrane proteins. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes. Accordingly, in one aspect, this invention provides isolated nucleic acid molecules encoding a polypeptide of the invention or biologically active portion thereof. The present invention also provides nucleic acid molecules which are suitable as primers or hybridization probes for the detection of nucleic acids encoding a polypeptide of the invention.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: April 10, 2007
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Samantha J. Busfield
  • Patent number: 6852837
    Abstract: Novel TANGO-69-receptor polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length TANGO-69-receptor proteins, the invention further provides isolated TANGO-69-receptor fusion proteins, antigenic peptides and anti-TANGO-69-receptor antibodies. The invention also provides TANGO-69-receptor nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a TANGO-69-receptor gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: August 21, 2001
    Date of Patent: February 8, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Samantha J. Busfield
  • Publication number: 20040265970
    Abstract: The present invention relates to the identification and characterization of a novel gene called don-1 related to epidermal growth factors (EGF) such as the neuregulins, and methods of preparing and using alternate splice forms of this gene to express new Don-1 polypeptides.
    Type: Application
    Filed: July 26, 2004
    Publication date: December 30, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: David P. Gearing, Samantha J. Busfield
  • Publication number: 20040176296
    Abstract: Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST proteins, the invention further provides isolated ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST fusion proteins, antigenic peptides and anti-ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST antibodies. The invention also provides ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Application
    Filed: March 22, 2004
    Publication date: September 9, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Douglas A. Holtzman, Sean A. McCarthy, Kyle J. MacBeth, Samantha J. Busfield, Yang Pan, David White, Mehran M. Khodadoust, Wei Gu
  • Publication number: 20030138912
    Abstract: The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1, 2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-A. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The ELVIS nucleic acids of the present invention are useful as modulating agents in regulating a variety of cellular processes, and are particularly useful for diagnostic, screening and therapeutic methods for the treatment of skin conditions, such as for wound healing.
    Type: Application
    Filed: January 16, 2003
    Publication date: July 24, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Samantha J. Busfield, David P. Gearing